Moderna’s AI-Built Cancer Vaccine Clears Phase 3 With Merck
Summary
Moderna and Merck said their Phase 3 trial of the personalized cancer therapy intismeran autogene met its primary endpoint in melanoma patients. The treatment uses tumor data to create an individualized vaccine for each patient.
A positive Phase 3 result moves AI-guided, patient-specific cancer vaccines closer to regulatory review and
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The result could validate a new cancer treatment model, but manufacturing and delivery will determine whether it can reach patients at scale.